Dr Ali McBride Discusses the Role of Biosimilars in Oncology

At the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center and president of ACCC, discussed the role of biosimilars in oncology and how familiar oncologists and their teams are with them.

Related Videos

Related Content

Advertisement

November 22nd 2024

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

Cameron Santoro

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).

Related Content

Advertisement

November 22nd 2024

Addressing Patent Hurdles, Payer Barriers, and Interchangeability

Cameron Santoro

Global Biosimilars Week discussed issues in biosimilar adoption and called for reforms to streamline processes, foster competition, and increase biosimilar access for patients.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

November 19th 2024

Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities

Kyle Munz

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

November 19th 2024

Drivers of Aggression Identified in Double-Expressor DLBCL

Jared Kaltwasser

Investigators say they may have found a new therapeutic target for patients with double-expressor diffuse large B-cell lymphoma (DLBCL).